Statement re Issuance of US Patent

PROTEOME SCIENCES plc

Issuance of US Patent for Isobaric Tandem Mass Tags® (TMT®)

13 November 2007.

Proteome Sciences plc ("Proteome Sciences") announces the issuance of US Patent
Number 7,294,456 entitled Mass Labels relating to isobaric tandem mass tags
(TMT®). Patents covering the TMT technologies are now issued in Australia, New
Zealand, Canada, Europe and the USA. The US Patent contains broad claims to
sets of isobaric mass tags.

Commenting on the Issuance of US Patent Number 7,254,456 Christopher Pearce,
CEO of Proteome Sciences said:

"Following the issuance of the TMT1 patent in Europe, we are delighted today to
have obtained the issuance of the TMT1 patent in the US. The issued TMT patents
provide Proteome Sciences broad claims across the field of isobaric tandem mass
tagging, with the ability to now exploit TMT® in these substantial markets both
as a product in its own right, and for third party licences for the manufacture
or use of any type of isobaric tandem mass tags.

The patent issuance should allow us to complete commercialisation and
outlicensing of TMT® and to generate strong revenue through licence income,
product sales and royalties in the rapidly growing market and applications for
isobaric tandem mass tagging in biomarker discovery, validation and assay
development across a broad range of applications including clinical research
and in vitro diagnostics."

                                     Ends                                      

Notes to editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications. It has discovered blood biomarkers
principally for stroke, vCJD, BSE, brain damage, solid organ transplant
rejection and Alzheimer's disease. The main focus of its research currently
addresses neurological, neurodegenerative, oncology and cardiovascular
conditions.

In addition to its own proprietary biomarkers, Proteome Sciences has developed
ProteoSHOP® (Proteome Sciences High Output Proteomics), a toolbox that offers
high sensitivity and high throughput gel and gel-free proprietary technologies
for the identification and validation of potential biomarkers and drug targets,
including specialisation in membrane proteins and protein phosphorylation.

The Company has developed a range of specialist reagents to improve the
performance and quantitation of protein separation and characterisation with
mass spectrometry, bioinformatics, statistics and pattern recognition. These
include Sensitizer®, PST®, qPST™ and TMT®. Proteome Sciences has patent
allowances in the major global jurisdictions for isobaric tandem mass tags (TMT
®) for the manufacture and use of any type of isobaric mass tags.

Commercialisation is actively pursued across the portfolio of the Company's
programmes and technologies with licensing deals signed in biomarkers for
Stroke and TSEs and for ProteoSHOP®.

Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has
laboratories at Kings College Hospital, London and Frankfurt Innovations
Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its
corporate and business development staff, and has collaborative research
agreements with leading academic institutes. The Company is listed on the
Alternative Investment Market.

For further information please visit www.proteomics.com .

Proteome Sciences plc

Dr. Ian Pike, Business Development Director
Email: [e-mail]

Christopher Pearce, Chief Executive Officer
Email: [e-mail]
Tel: [phone]

                               Public Relations                                

IKON Associates Coast Communications

Adrian Shaw 
Tel: [phone] 
Mobile: [phone]
Email: [e-mail]

Matt Baldwin
Tel: [phone]
Mobile: [phone]
Email: [e-mail]

Nominated Adviser

Landsbanki Securities (UK) Ltd

Gareth Price / Thilo Hoffman Tel: [phone]